|Calculated MW||147870 Da|
|Other Names||1-phosphatidylinositol 4, 5-bisphosphate phosphodiesterase gamma-2, Phosphoinositide phospholipase C-gamma-2, Phospholipase C-IV, PLC-IV, Phospholipase C-gamma-2, PLC-gamma-2, PLCG2|
|Target/Specificity||A synthetic peptide corresponding to residues near the C-terminus of human PLCγII was used as an immunogen.|
|Format||50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||PLC-II Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||The production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) is mediated by activated phosphatidylinositol-specific phospholipase C enzymes. It is a crucial enzyme in transmembrane signaling.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Enzymes of the phospholipase C family catalyze the hydrolysis of phospholipids to yield diacylglycerols and water-soluble phosphorylated derivatives of the lipid head groups. The phospholipase C gamma-2 (PLCγII) is an enzyme that plays a crucial role in intracellular signal transduction pathways. This enzyme is important because of its role in the generation of second messengers following the hydrolysis of phosphatidylinositol 4,5-bisphosphate (1). PLCγII has been implicated in collagen-induced signal transduction in platelets and antigen-dependent signaling in B-lymphocytes. It has been suggested that tyrosine kinases activate PLCγII (2). It has also been shown that PLCγII was required for receptor activator of NF-kappaB ligand-induced (RANKL-induced) osteoclastogenesis by differentially regulating nuclear factor of activated T cells c1 (NFATc1), activator protein-1 (AP1), and NF-kappaB (3).
1. Argeson AC, et al. Genomics 25(1):29-35, 1995.
2. Ozdener F, et al. Mol Pharmacol 62(3):672-9, 2002.
3. Mao D, et al. J Clin Invest 166(11):2869-79, 2006.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.